PORTLAND, Ore., March 16 /PRNewswire/ -- Bioject Medical Technologies Inc.
(Nasdaq: BJCT), the leading manufacturer of jet injection devices for
needle-free drug delivery and developer of a continuous ambulatory blood
glucose monitoring system, today announced that phase I human trials have
begun with Vaxid, a DNA-based vaccine for the treatment of lymphoma using the
Biojector 2000(R) jet injector as a delivery system.
The study, sponsored by Vical Incorporated (Nasdaq: VICL), is being
conducted at the Stanford University Medical Center under the direction of Dr.
John Timmerman and Dr. Ronald Levy, the primary investigators. The Biojector
2000(R) is being used in comparison with needle and syringe because other
studies suggest that the Biojector 2000(R) may be a more optimal route of
delivery for DNA-based vaccines.
"Bioject is committed to developing new applications for our portfolio of
needle-free jet injection systems," said Jim O'Shea, Bioject's chairman,
president and CEO. "We are pleased that our needle-free technology can be
used to enhance the delivery of DNA-based vaccines for the treatment of
cancer, a promising new alternative for patients."
Bioject Medical Technologies develops, manufactures and markets jet
injection systems for needle-free subcutaneous and intramuscular injections.
The Company's advanced injection management system, the Biojector 2000(R), has
received the Seal of Acceptance from the Alliance of Children's Hospitals,
Inc. In a joint venture with Elan Corporation, Bioject is developing an
ambulatory, continuous blood glucose monitoring system for diabetes patients.
|
